CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
61 hedge funds and large institutions have $26.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 23 reducing their positions, and 13 closing their positions.
3% less capital invested
Capital invested by funds: $27.5M → $26.7M (-$846K)
9% less funds holding
Funds holding: 67 → 61 (-6)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
65% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$601K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$155K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$29.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$28.4K |
| 5 |
FNYS
First New York Securities
New York
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.42M |
| 2 |
Millennium Management
New York
|
-$792K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$292K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$268K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$153K |
CTIC Hedge Fund Activity: Q3 2016 in Review
61 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2016, worth a combined $26.7M — down 3.1% from $27.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CTIC and 8 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $601K. The largest seller was Fidelity Investments, cutting an estimated $2.42M.
- 61 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2016, down from 67 in Q2 2016.
- Funds reported $26.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2016, down 3.1% quarter-over-quarter.
- 8 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2016 and 13 closed out, a net change of -5 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2016 was Renaissance Technologies, an estimated $601K added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2016 was Fidelity Investments, an estimated $2.42M sold.
Based on aggregated 13F filings for Q3 2016.